Nanobody is one special type of single-domain antibody fragment with multiple advantages over traditional antibody. Our previous work established linear-double-stranded DNA (ldsDNA, or PCR amplicon) as novel biological parts for building AND gate circuits in mammalian cells. The construction process of the ldsDNA-based AND gate genetic circuits is similar to that of V(D)J recombination, which serves as the genetic principle for the generation of antigen-receptor (antibody and T-cell receptor) diversity. Here, we employed this ldsDNA-based AND-gate strategy to construct nanobody library in mammalian cells. The sequence complexity of complementary determining regions (CDRs) was introduced into ldsDNA by PCR amplification. After being co-transfected into mammalian cells, the up-and down-stream ldsDNAs undergo AND gate linkage and form full nanobody coding regions, containing CDR1-3. High throughput sequencing identified 22,173 unique oligonucleotide sequences in total generated by this strategy. Thus, we developed a novel method to construct nanobody library in mammalian cells, which has a great potential in the development of nanobody-therapeutics.
Introduction
Nanobody, also known as single-domain antibody (sdAb) or domain antibody, is one special type of antibody consisting of a single monomeric variable antibody domain (1, 2) . Since being first discovered in camelids in 1993, nanobody has been serving as a good platform for the development of therapeutic antibody due to its advantages such as small size (~15 kDa, 4 nm long and 2.5 nm wide), high stability, high solubility and excellent tissue penetration ability (2) (3) (4) (5) (6) . In 2019, the first nanobody-based medicine, Cablivi® (caplacizumab), was approved by FDA for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) (7) . Meanwhile, multiple other nanobodies are currently under clinical development (7, 8) .
Different state-of-the-art display technologies, e.g., phage, bacteria, yeast, ribosome, and mRNA-display, are used to identify candidate nanobodies from large-size nanobody libraries (9) (10) (11) (12) (13) (14) (15) .
These technologies associate the phenotype (affinity between nanobody and antigen) to the genotype (DNA sequence of nanobody). After rounds of selection, by Sanger or high throughput sequencing, the sequences encoding high affinity nanobodies can be obtained (5) . However, in current display technologies, nanobodies are generated and displayed in non-mammalian systems, which greatly limits their applications. Mammalian cells are good platforms for antibody development, as the appropriate protein chemical modification, and natural folding structure of the transmembrane proteins.
Ingenious design methods, such as mammalian cell surface display, and autocrine-based signaling system, have been developed to facilitate the panning of antibody in human cell lines (16) (17) (18) (19) (20) .
However, there is still a lack of methods for building highly diverse nanobody library in mammalian cells. got 4,173,356 reads. About 88.18% of merged reads (3, 679, 989) contain both upstream-and downstream-ldsDNA sequence and were subjected to further investigation.
Length distribution of nanobody ldsDNA sequences formed by AND gate genetic circuit
In the NHEJ pathway, genomic dsDNA ends are subject to terminal processing, leading to either nucleotide(s) deletion or insertion (30) . Our previous research also revealed that ldsDNAs transfected into HEK293T cells undergo end nucleotide(s) deletion (23). To evaluate ldsDNA ends processing during AND gate formation, we analyzed the length distribution of nanobody ldsDNAs. If terminal deletion or insertion happens to input ldsDNA, the length of full nanobody ldsDNA would change. As shown in Figure 2 , the most abundant read length is 264-bp (154,477 reads), which is corresponding to the intact sequence length (implying that neither deletion nor insertion happens to ldsDNA ends) ( Figure 2A ). That is these most abundant 264-bp reads followed the same framework with GFP-nanobody (for sequence see Supplementary Materials). Other top read length is shorter than 264-bp ( Figure 2A ). Thus, we can conclude that ldsDNA terminals usually undergo end nucleotide(s) deletion, not insertion.
Abundance distribution of full nanobody ldsDNA sequences
In different display platforms, the capacity of the nanobody library usually serves as a determining factor of a successful experiment. The diversity of our nanobody library comes from 2 levels: the diversity of the input ldsDNAs and the combining diversity in the process of upstream-and downstream-ldsDNA linkage. In 154,477 reads of 264-bp full nanobody subset from all 3 biological repeats, we got 22,172 unique sequences. The two most abundant sequences have more than one thousand reads (1,117 and 1,044 reads respectively). There are 298 sequences containing 101 to 1,000 reads. And 19,737 sequences have only one read ( Figure 2B ). Meanwhile, we investigated the redundancy among different biological repeats. As showed by the Venn diagram, only one sequence was present in all three independent nanobody libraries ( Figure 2C ). Thus, this demonstrates that there is no obvious library redundancy when scaling up the experiments.
Nucleotide and amino acid distribution of nanobody library CDRs
We next analyzed the nucleotide distributions of CDRs in 22,172 unique 264-bp sequences. As shown in Figure 3A -C, nucleotide frequencies in each codon of the three CDRs are all in accordance with the NNK pattern. We also analyzed the composition of amino acid encoded by nanobody library CDR ( Figure 3D ). The STOP codon accounts for 2.64% in all CDR codons, which is lower than the theoretical frequency of the NNK degenerate codon (3.125%). The chance to get a pre-STOP codon increases with the elongation of the NNK peptide chain. When there are 24 NNK codons (8 in CDR1, 9 in CDR2, 7 in CDR3), the theoretical ratio of translation pre-termination is 46.7%. In our nanobody library, pre-STOP codon presents in 9,577 of the total 22,172 unique sequences (43.2%).
Discussion
Here using ldsDNA-based AND-gate genetic circuit, we developed a novel method to construct nanobody library in mammalian cells. This protocol is easy to conduct, containing only two steps:
PCR amplification and transfection of mammalian cell lines. Via PCR amplification, we introduce the CDRs into the upstream-and downstream-ldsDNAs respectively, which are then co-transfected into mammalian cell line to form AND-gate genetic circuits and launch the expression of full-length nanobodies. Through the linkage process, the diversity of the nanobody library is further increased. This process is similar to that of V(D)J recombination, which serves as the fundamental mechanism of the generation of highly diverse repertoires of antibody or T-cell receptor. Through high throughput sequencing, we identified a total of 22,172 unique full-length sequences. And we further compared the library content among three independent biological repeats and found the non-redundant property of the nanobody library. These results demonstrate the feasibility of our strategy.
In this study, we employ GFP-nanobody as the framework of our library. Although GFP-nanobody has a high affinity for GFP (Kd = 0.32 nM), the length of its CDR3 (7AA) is much shorter than that of typical nanobodies (16-18AA) (1, 5, 26) . Longer CDR3 is believed to contribute more antigen-binding conformation, which, to some extent, makes up for the decrease of binding capacity caused by the lack of light chain in nanobody. In future application, we can obtain nanobody library with longer CDR3 via utilizing longer PCR primers for downstream ldsDNAs. Another hallmark of nanobody is the interloop disulfide bond formed between CDR1 and CDR3. The disulfide bond stabilizes the domain and rigidifies the long CDR3 loop leading to stronger antigen interaction (31). By introducing Cysteine codons into both upstream-and downstream-ldsDNAs via primers, we could also establish interloop disulfide bonds in the nanobody library.
Here, our strategy is demonstrated to be feasible. However, there is still much room to improve on the efficiency of nanobody library construction. First, input ldsDNAs are frequently subjected to terminal nucleotide(s) deletion before their linkage. In our nanobody library, only 4.2% of the merged clean reads (154,477 / 3,679,989) contain the intact GFP-nanobody framework, although it is still the most abundant read length. Most of the other top read length are shorter than the intact framework, which is supposed to be the outcome of terminal nucleotide deletion (Figure 2A ). Terminal nucleotide(s) deletion of input ldsDNAs causes the loss of coding fragments and the destruction of nanobody framework, which leads to the shrinkage of the library size. One potential solution is to generate nuclease resistant ldsDNAs by introducing chemical modification into PCR products. We designed phosphorothioate-modified primers and introduced this modification into ldsDNAs via PCR amplification. However, we found that the presence of phosphorothioate bonds could block the formation of AND-gate genetic circuit (data not shown). Second, NNK degenerate codon brings biased amino acid composition and unwanted pre-stop and Cysteine codons. There is redundancy in both natural and NNK degenerate codon. For example, there are six and three Leucine coding codons in natural and NNK codes, respectively. For Phenylalanine, only one codon exists in both categories.
This difference could lead to biased amino acid distribution ( Figure 3D ). The presents of pre-stop codon could also cut down the library size. In our nanobody library, 43.2% of 22,172 unique sequences contain pre-stop codon. And Cysteine could form disulfide bond with another Cysteine, which may interfere the tertiary structure of nanobody. We can synthesize primers by using trimer phosphoroamidites to get more balanced random CDRs meanwhile avoiding pre-stop and Cysteine codons (32,33).
In summary, we applied ldsDNA-based AND gate genetic circuit to generate highly diverse nanobody library, which may have great application potential in therapeutic nanobody development. Figure 1 . Schematic diagram of the generation of ldsDNA and the formation of ldsDNA-based AND-gate genetic circuit. (A) Schematic showing the rationale of introducing CDR1 and CDR2 random sequence into up-stream ldsDNA by PCR amplification. In the primer annealing step, the 3' primer binds to single-stranded template DNA through its 3' fragment (21-bp). In the extending step, DNA polymerase would synthesize a complementary strand by taking the 5' fragment of 3' primer as template. Thereby, CDR1 and CDR2 sequences are incorporated into up-stream ldsDNAs. (B) In HEK293T cells, the up-and down-stream ldsDNAs link together through AND-gate calculation to form nanobody library generating full-length ldsDNAs. [Barcode]ATGATGTTTAGAAG AAACAGTAACT N = T or C or A or G; K = T or G; M = C or A.
Figure Legends
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Template ldsDNA sequences in study:
>Up -stream template ldsDNA   CAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTT  CGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATTAATAGTAA  TCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGG  TAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGT  ATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGACTATTTAC  GGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTG  ACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACT  TTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTG  GCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCC  CATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCG  TAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATAT  AAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATAC  GACTCACTATAGGGAGACCCAAGCTTGGTACCGCCACCATGGAGACAGACACACTCCTGC  TATGGGTACTGCTGCTCTGGGTTCCAGGTTCCACTGGTGACTATCCATATGATGTTCCAGA  TTATGCTATGCAAGTTCAATTGGTTGAATCTGGTGGTGCTTTGGTTCAACCTGGTGGTTCT  TTGCGTTTGTCTTGTGCTGCTTCT   > Down-stream template ldsDNA   TATTGGGGTCAAGGTACTCAAGTTACTGTTTCTTCTAAACATCATCATCATCATCATGAAC  AAAAACTCATCTCAGAAGAGGATCTGAATGCTGTGGGCCAGGACACGCAGGAGGTCATC  GTGGTGCCACACTCCTTGCCCTTTAAGGTGGTGGTGATCTCAGCCATCCTGGCCCTGGTGG  TGCTCACCATCATCTCCCTTATCATCCTCATCATGCTTTGGCAGAAGAAGCCACGTTAGTC  TAGAGGGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTG  TGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAA  GGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTA  GGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAA  GACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAAC  CAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGG 
